Abstract
There is a compelling need to develop anticancer therapies that target cancer cells and tissues. Arising from innovative femtomedicine studies, a new class of non-platinum-based halogenated molecules (called FMD molecules) that selectively kill cancer cells and protect normal cells in treatments of multiple cancers has been discovered. This article reports the first observation of the radiosensitizing effects of such compounds in combination with ionizing radiation for targeted radiotherapy of a variety of cancers. We present in vitro and in vivo studies focused on combination with radiotherapy of cervical, ovarian, head and neck, and lung cancers. Our results demonstrate that treatments of various cancer cells in vitro and in vivo mouse xenograft models with such compounds led to enhanced efficiencies in radiotherapy, while the compounds themselves induced no or little radiotoxicity toward normal cells or tissues. These compounds are therefore effective radiosensitizers that can be translated into clinical trials for targeted radiotherapy of multiple types of cancer. This study also shows the potential of femtomedicine to bring breakthroughs in understanding fundamental biologic processes and to accelerate the discovery of novel drugs for effective treatment or prevention of a variety of cancers. © 2016 American Association for Cancer Research.
| Original language | English |
|---|---|
| Pages (from-to) | 640-650 |
| Journal | Molecular Cancer Therapeutics |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1 Apr 2016 |
| Externally published | Yes |
Bibliographical note
Publication details (e.g. title, author(s), publication statuses and dates) are captured on an “AS IS” and “AS AVAILABLE” basis at the time of record harvesting from the data source. Suggestions for further amendments or supplementary information can be sent to [email protected].Funding
This study was supported by an operating grant #102483 (to Q.-B. Lu, D.A. Jaffray, and R.G. Bristow), a New Investigator Award #112642 (to Q.-B. Lu) from the Canadian Institutes of Health Research, a Discovery grant #299089 (to Q.-B. Lu) from Natural Science and Engineering Research Council of Canada, and an Early Researcher Award # 41477 (to Q.-B. Lu) from the Ontario Ministry of Research and Innovation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
